Supplemental Table 1: PCR primers used to generate DNA fragments required to assemble IL-2/CD25 FPs				
Primer	Description	Orientation	Primer	Purpose
1	pCIneo/Xho/koz/r	Reverse	5' ccatggtggcctcgaggctagcctatagtg	Amplify and modify
2	pCIneo/Not/lnk2/6xhis/stop/f	Forward	5' ggtggacatcaccatcaccatcactaataagcggccgcttccctttag	pCIneo vector
3	pCI/Koz/mIL2/f	Forward	5'aatacgactcactataggctagcctcgaggccaccatggacagcatgcagctcgcatcc	Amplify mIL-2 fragments
4	mIL2/lnk7/IL2ra/r	Reverse	cagacacagttcacctccacctccacctccaccttgagggcttgttgagatgatg	
5	mIL2/$(G3S)_3$/r	Reverse	5' cgaacctccacctgaacctccaccagaacctccaccttgagggctt	
6	mIL2/$(G4S)_4$/r	Reverse	5' tccacctccacctgatccacctccaccagatccacctccaccttgagggctt	
7	mIL2/$(G4S)_5$/r	Reverse	5' ccacctgatccacctccaccagatccacctccacctgatccacctccaccttgagggctt	
8	$(G3S)_3$/mCD25/f	Forward	5' ggtggaggttctggtggaggttcaggtggaggttcggaactgtgtctgtatgaccc	Amplify mCD25 fragments
9	$(G3S)_4$/mCD25/f	Forward	5' tctggtggaggttcaggtggaggttcgggtggaggttctgaactgtgtctgtatgaccc	with various linkers
10	$(G4S)_4$/mCD25/f	Forward	5' ggtggatcaggtggaggtggatccggtggaggtggatctgaactgtgtctgtatgaccc	
11	$(G4S)_5$/mCD25/f	Forward	5' aggtggatcaggtggaggtggatccggtggaggtggatctgaactgtgtctgtatgaccc	
12	mCD25/lnk/6xHis/stop/r	Reverse	5' ttattagtgatggtgatggtgatgtccaccaacttgagggcttgttgagatgatg	
13	$(G3S)_3$/hCD25/lnk12/f	Forward	5' ggtggaggttctggtggaggttcaggtggaggttcggagctctgtgacgatgaccc	Amplify hCD25 fragment
14	hCD25/lnk/6xHis/r	Reverse	5' gtgatggtgatggtgatgtccaccctggtactctgttgtaaatatgga	with 12 amino acid linker

Note: Fragment of mCD25 from primers 8/12 was used with the fragments of mIL-2 from primers 3/5 and 3/6 to generate mIL-2/mCD25 with 12 and 16 amino acid $(G3S)_3$ and $(G3S)_4$ linkers.



Supplemental Figure 1. Representative FACS histograms of $CD4^+$ $Foxp3^+$ and $CD4^+$ $Foxp3^-$ T cells from C57BL/6 and NOD-Foxp3/RFP (NOD/FIR) spleen cells after in vitro stimulation with the indicated concentrations of mIL-2 (top histograms) or mIL-2/mCD25 (bottom histograms).



Supplemental Figure 2. Effect of mIL-2/mCD25 on T cells in male BALB/c mice.A) Mice (n=5/group) were treated with FC-mIL-2 on days 0, 2, 4, and 6 or with PBS or mIL-2/mCD25 on days 0, 2, and 6. 24 hr after the last injection, the numbers of the indicated T cell populations in the spleen were enumerated by FACS analysis. B) Mice (n=5/group) were treated with PBS or mIL-2 daily for 9 days or with mIL-2/mCD25 on days 0, 3, 6, and 9. 24 hr after the last injection, the percentage and numbers of the indicated T cell populations in the spleen were enumerated by FACS analysis. Data are shown as the mean ± SEM. Numbers within the graphs represent the p values, which were determined by the Krukal-Wallis one way ANOVA using the Dunn's multiple comparison test in relationship to the PBS control treated group.



Supplemental Figure 3. Representative FACS plots for expression of CD25 and Ki67 (A) and CD44 vs CD62L (B) for the indicated cell populations 2-3 days after NOD mice received twice weekly injections of mIL-2/mCD25 FP (4 μg) for 5 weeks. The numbers on each plot represent the percent positive cells within the indicated gate.